主 办:北 京 中 医 药 大 学
ISSN 1006-2157 CN 11-3574/R

JOURNAL OF BEIJIGN UNIVERSITY OF TRADITIONAL CHINE ›› 2016, Vol. 39 ›› Issue (4): 316-319.doi: 10.3969/j.issn.1006-2157.2016.04.010

Previous Articles     Next Articles

Comparison of serum level of methylglyoxal, adiponectin and vascular endothelial growth factor in patients with diabetic kidney disease at early stage and at clinical stage*

ZHANG Xiangwei1, LIU Hongfang2#, CUI Zhaoli3, ZHU Ying4   

  1. 1 Beijing University of Chinese Medicine, Beijing 100029;
    2 Dongzhimen Hospital, Beijing University of Chinese Medicine;
    3 Dongzhimen Hospital East Area, Beijing University of Chinese Medicine;
    4 The Third Affiliated Hospital of Beijing University of Chinese Medicine
  • Received:2015-11-26 Online:2016-04-30 Published:2016-04-30

Abstract: Objective To study the differences of serum methylglyoxal (MGO),adiponectin (APN)and vascular endothelial growth factor (VEGF)in patients with diabetic kidney disease (DKD)at early stage and at clinical stage. Methods Patients with DKD collected from 2012 to 2014 in the hospitals were grouped by stage (early stage group: 152 cases, clinical stage group: 56 cases). All the patients were treated with conventional therapy, including hypoglycemic drugs and antihypertensive drugs. Serum of all patients was collected and detected at the beginning (baseline) and after six months. Serum MGO, APN and VEGF were measured using ELISA and compared inter-group and intra-group. Results Compared with the early stage group, the levels of serum MGO and VEGF in clinical stage group were higher at the beginning and after six months(P<0.05), while the level of APN showed no difference. In the early stage group, the level of serum APN got higher after six months than that at the beginning(P<0.05),with no significant change in MGO, VEGF. There were no significant difference in MGO, APN and VEGF in clinical stage group in six months(P>0.05). Conclusion The increasing of serum MGO and VEGF which suggested the progression of early DKD, may provide some references for risk assessment of DKD patients at early stage.

Key words: diabetic kidney disease, methylglyoxal, adiponectin, vascular endothelial growth factor

CLC Number: 

  • R255.4